Crónicas de autores

Mariano Provencio *

Autor invitado por SIIC

El trabajo muestra la eficacia del tratamiento de consolidación con Y90-ibritumomab tiuxetan en el linfoma folicular.

EFICACIA DEL TRATAMIENTO DE CONSOLIDACIÓN EN EL LINFOMA FOLICULAR

El tratamiento de consolidación con Y90-ibritumomab tiuxetan produce mejoría clínica. En comparación con la terapia de inducción, es un tratamiento eficaz y presenta una toxicidad manejable.

*Mariano Provencio
describe para SIIC los aspectos relevantes de su trabajo
CONSOLIDATION TREATMENT WITH YTTRIUM-90 IBRITUMOMAB TIUXETAN AFTER NEW INDUCTION REGIMEN IN PATIENTS WITH INTERMEDIATE - AND HIGH RISK FOLLICULAR LYMPHOMA ACCORDING TO THE FOLLICULAR LYMPHOMA INTERNATIONAL PROGNOSTIC INDEX: A MULTICENTER, PROSPECTIVE
Leukemia & Lymphoma,
55(1):51-55 Ene, 2014

Esta revista, clasificada por SIIC Data Bases, integra el acervo bibliográfico
de la Biblioteca Biomédica (BB) SIIC.

Institución principal de la investigación
*Hospital Universitario Puerta de Hierro Majadahonda, Madrid, España
Imprimir nota
Referencias bibliográficas
Chamarthy MR, Williams SC, Moadel RM. Radioimmunotherapy of non-Hodgkin's lymphoma: from the 'magic bullets' to 'radioactive magic bullets'. Yale J Biol Med 84:391-407, 2011.
Press OW, Unger JM, Braziel RM, Maloney DG, Millar TP, LeBlanc M, et al. A phase 2 trial of CHOP chemotherapy followed by tositumomab/iodine I 131 tositumomab for previously untreated follicular non-Hodgkin lymphoma: Southwest Oncology Group Protocol S9911. Blood 102:1606-1612, 2003.
Press OW, Unger JM, Braziel RM, Maloney DG, Millar TP, LeBlanc M, et al. Phase II trial of CHOP chemotherapy followed by tositumomab/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin's lymphoma: five-year follow-up of Southwest Oncology Group Protocol S9911. J Clin Oncol 24:4143-4149, 2006.
DeMonaco NA, Wu M, Osborn J, Evans T, Foon KA, Swerdlow SH, et al. Phase II trial of abbreviated CHOP-rituximab followed by 90Y ibritumomab tiuxetan (ybritumomab tiuxetan) and rituximab in patients with previously untreated follicular LNH. Blood 106(11):abs 2449, 2005.
Zinzani PL, Tani M, Pulsoni A, De Renzo A, Stefoni V, Broccoli A, et al. A phase II trial of short course fludarabine, mitoxantrone, rituximab followed by 90Y-ibritumomab tiuxetan in untreated intermediate/high-risk follicular lymphoma. Ann Oncol 43:415-420, 2012.
Radford JA, Ketterer N, Sebban C. Ibritumomab tiuxetan (ybritumomab tiuxetan) therapy is feasible and safe for the treatment of patients with advanced B-cell follicular lymphoma: Interim analysis for safety of a multicenter phase III clinical trial. Blood 102:408, 2003.
Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 17:1244, 1999.
Jacobs SA, Swerdlow SH, Kant J, Foon KA, Jankowitz R, Land SR et al. Phase II trial of short-course CHOP-R followed by 90Y-ibritumomab tiuxetan and extended rituximab in previously untreated follicular lymphoma. Clin Cancer Res 14:7088-7094, 2008.
Hainsworth JD, Spigel DR, Markus TM, Shipley D, Thompson D, Rotman R, et al. Rituximab plus short-duration chemotherapy followed by Yttrium-90 Ibritumomab tiuxetan as first-line treatment for patients with follicular non-Hodgkin lymphoma: a phase II trial of the Sarah Cannon Oncology Research Consortium. Clin Lymphoma Myeloma 9:223-228, 2009.
Zinzani PL, Tani M, Pulsoni A, Gobbi M, Perotti A, De Luca S, et al. Fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in previously untreated patients with follicular non-Hodgkin lymphoma trial: a phase II non-randomised trial (FLUMIZ). Lancet Oncol 9:352-358, 2008.
Morschhauser F, Radford J, Van Hoof A, Vitolo U, Soubeyran P, Tilly H, Huijgens PC, Kolstad A, d'Amore F, Gonzalez Diaz M, Petrini M, Sebban C, Zinzani PL, Van Oers MH, Van Putten W, Bischof-Delaloye A, Rohatiner A, Salles G, Kuhlmann J, Hagenbeek A. Phase III trial of consolidation therapy with ytrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma. J Clin Oncol 26:5156-64, 2008.
Press OW, Unger JM, Rimsza LM, Friedberg JW, Leblanc M, Czuczman MS, Kaminski M, Braziel RM, Spier C, Gopal AK, Maloney DG, Cheson BD, Dakhil SR, Miller TP, Fisher RI. Phase III randomized intergroup trial of CHOP plus rituximab compared with CHOP chemotherapy plus 131iodine-tositumomab for previously untreated follicular non-Hodgkin lymphoma: SWOG S0016. J Clin Oncol 2012 [Epub ahead of print].
Salles G, Seymour JF, Offner F, López-Guillermo A, Belada D, Xerri L, Feugier P, Bouabdallah R, Catalano JV, Brice P, Caballero D, Haioun C, Pedersen LM, Delmer A, Simpson D, Leppa S, Soubeyran P, Hagenbeek A, Casasnovas O, Intragumtornchai T, Fermé C, Da Silva MG, Sebban C, Lister A, Estell JA, Milone G, Sonet A, Mendila M, Coiffier B, Tilly H. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet 377:42-51, 2011.
Otros artículos de Mariano Provencio

Provencio M, Sánchez A, Artal A, Sánchez Torres JM, De Castro J, Dómine M, Viñolas N, Sánchez A, Pérez FJ. Cisplatin plus oral vinorelbine as first-line treatment for advanced non-small-cell lung cancer: a prospective study confirming that the day-8 hemogram is unnecessary. Clin Transl Oncol (8):659-64, 2013. doi: 10.1007/s12094-012-0989-6.
Provencio M, Sánchez A, Sánchez-Beato M. New drugs and targeted treatments in Hodgkin's Lymphoma. Cancer Treat Rev 2013. doi:pii: S0305-7372(13)00194-1. 10.1016/j.ctrv.2013.09.005. [Epub ahead of print].
Provencio M, Cruz Mora MA, Gómez Codina J, Quero Blanco C, Llanos M, García Arroyo FR, De la Cruz L, Gumá Padró J, Delgado Pérez JR, Sánchez A, Álvarez Cabellos R, Rueda A; On behalf of the GOTEL (Spanish Lymphoma Oncology Group). Consolidation treatment with Yttrium-90 ibritumomab tiuxetan after a new induction regimen in intermediate and high-risk follicular lymphoma patients according to the follicular lymphoma international prognostic index (FLIPI): A multicenter, prospective Phase II trial of Spanish Lymphoma Oncology Group. Leuk Lymphoma 55(1):51-5, 2014.
Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, Palmero R, García-Gómez R, Pallares C, Sánchez JM, Porta R, Cobo M, Garrido P, Longo F, Moran T, Insa A, De Marinis F, Corre R, Bover I, Illiano A, Dansin E, De Castro J, Milella M, Reguart N, Altavilla G, Jiménez U, Provencio M, et al. Erlotinib versus chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncology 2012.
López-Guillermo A, Caballero D, Canales M, Provencio M, Rueda A, Salar A. Clinical practice guidelines for first-line/alter-relapse treatment of patients with follicular lymphoma. Leuk Lymphoma 52(S3):1-14, 2011.
Martin P, Gómez-Lozano N, Montes S, Salas C, Provencio M, Bellas C. Epstein-Barr virus in the germinal centres of adenopathies affected by classic Hodgkin lymphoma. Histopathology 59(2):349-52, 2011.
Martin P, Salas C, Provencio M, Abraira V, Bellas C. Heterogeneous expresión of Src tyrosine kinases Lyn, Fyn, and Syk in classical Hodgkin lymphoma: prognostic implications. Leukemia and Lymphoma 2011.
Cutuli B, Kanoun S, Tunon De Lara C, Baron M, Livi L, Levy C, Cohen-Solal-Lenir C, Lesur A, Kerbrat P, Provencio M, Gonzague-Casabianca L, Mege A, Lemanski C, Delva C, Lancrenon S, Velten M. Breast cancer occurred after Hodgkin´s disease: clinico-pathological features, treatments and outcome: Analysis of 214 cases. Crit Rev Oncol Hematol 2011.

Para comunicarse con Mariano Provencio mencionar a SIIC como referencia:
acsr71@hotmail.com

Autor invitado
5 de marzo, 2014
Descripción aprobada
18 de marzo, 2014
Reedición siicsalud
7 de junio, 2021

Acerca del trabajo completo
EFICACIA DEL TRATAMIENTO DE CONSOLIDACIÓN EN EL LINFOMA FOLICULAR

Título original en castellano
TRATAMIENTO DE CONSOLIDACION CON Y90-IBRITUMOMAB TIUXETAN TRAS QUIMIOTERAPIA DE INDUCCION EN PACIENTES LINFOMA FOLICULAR DE INTERMEDIO Y ALTO RIESGO SEGUN EL INDICE PRONOSTICO INTERNACIONAL: ESTUDIO FASE II MULTICENTRICO Y PROSPECTIVO DEL GRUPO ONCO

Autor


Acceso a la fuente original
Leukemia & Lymphoma
http://informahealthcare.com/loi/lal

El artículo se relaciona estrictamente con las especialidades de siicsalud


ua40317